Abstract
To the Editor: In a recent study, Walsh, et al 1 sought to compare 3 published, validated screening tools for psoriatic arthritis (PsA): the Psoriasis Epidemiology Screening project (PEST), the Toronto Psoriatic Arthritis Screen (ToPAS), and the Psoriatic Arthritis Screening and Evaluation (PASE)2,3,4,5. We would like to address how PASE may not have been appropriately compared in this setting. The PASE questionnaire, developed by our group, is the only one of these 3 tools where scores have demonstrated sensitivity to change with disease activity6. PASE has similarly been shown to correlate with response to therapy7. PASE was … Address correspondence to Dr. A.A. Qureshi, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA; E-mail: aqureshi{at}bics.bwh.harvard.edu
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
